LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test Measures Hepatic Fibrosis Progression

By LabMedica International staff writers
Posted on 20 Jan 2015
Print article
Image: The automated immunoassay system HISCL-5000 series (Photo courtesy of Sysmex).
Image: The automated immunoassay system HISCL-5000 series (Photo courtesy of Sysmex).
Viral hepatitis is the most prevalent infectious disease in Japan, affecting some three million people and left untreated, the condition can develop into severe illness as it progresses toward liver cell carcinoma.

As chronic hepatitis advances toward liver cell carcinoma, the amount of fiber-rich tissue in the liver increases and hepatic function gradually declines. An important part of the treatment process for viral chronic hepatitis is determining the degree of hepatic fibrosis. The typical testing process involves taking a biopsy of the liver tissue, requiring a patient to be hospitalized because of its high invasiveness. This places a substantial burden on the patient on both the physical and economic fronts.

A hepatic fibrosis test reagent called HISCL M2BPGi Assay Kit (Sysmex; Kobe, Japan) was developed for testing the degree of viral hepatitis-induced disease during blood testing and is to be used on automated immunoassay systems—the Sysmex HISCL-Series HISCL-5000/2000i/800. The assay requires only a blood sample to determine within just about 17 minutes the status of progression of hepatic fibrosis to chronic hepatitis and cirrhosis of the liver, which has been suspected to be a cause of hepatocellular carcinoma. The hepatic fibrosis test reagent HISCL M2BPGi Assay Kit has been approved for insurance coverage domestically as of January 1, 2015.

The assay measures Mac-2 Binding Protein (M2BP) Glycosylation isomer and uses a chemiluminescent enzyme-linked immunoassay using a two-step sandwich method. Sugar chains, the linked monosaccharides that link to the surface of a cell or a protein, are sometimes described as "cell and protein costumes." Their roles include the transmission of information specific to individual cells and intercellular communications. A glycosylation marker is a biomarker that targets structural changes in sugar changes present in glycoproteins. The product will be introduced to the domestic market with the focus on medical facilities and diagnostic centers. Introductions to Asian countries, specifically China with its large number of liver disease patients, will follow in order.

Related Links:

Sysmex


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more